Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mixue Xie

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Platelets|December 27, 2019
A megakaryocyte morphological classification-based predictive model for steroid sensitivity in primary immune thrombocytopeniaJingjing Zhu, Rongrong Chen, Shuqi Zhao, et al.
Leukemia|June 14, 2020
Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infectionChunmei Yang, Mixue Xie, Kaifeng Zhang, et al.
Cell Death & Disease|January 2, 2019
Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversalMixue Xie, Apeng Yang, Jiexian Ma, et al.
Blood Cancer Journal|February 13, 2025
Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation blockJiexian Ma, Shunrong Sun, Yanhui Xie, et al.
Medicine|January 5, 2019
PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancerQi Jiang, Mixue Xie, Mengye He, et al.
Cancer|March 7, 2023
Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemiaMixue Xie, Ting Shi, Qi Jiang, et al.
Cancers|August 7, 2021
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-AnalysisWen Lei, Mixue Xie, Qi Jiang, et al.
Cancer Cell International|July 27, 2021
Significance of initial, interim and end-of-therapy <sup>18</sup>F-FDG PET/CT for predicting transformation risk in follicular lymphomaMixue Xie, Lulu Wang, Qi Jiang, et al.
Frontiers in Immunology|September 15, 2022
Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developmentsQi Jiang, Mixue Xie, Ruyin Chen, et al.
Blood Cancer Journal|November 2, 2025
Glofitamab combined with tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: a single-center pilot trialDe Zhou, Wenjuan Yu, Mixue Xie, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Platelets|December 27, 2019
A megakaryocyte morphological classification-based predictive model for steroid sensitivity in primary immune thrombocytopeniaJingjing Zhu, Rongrong Chen, Shuqi Zhao, et al.
Leukemia|June 14, 2020
Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infectionChunmei Yang, Mixue Xie, Kaifeng Zhang, et al.
Cell Death & Disease|January 2, 2019
Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversalMixue Xie, Apeng Yang, Jiexian Ma, et al.
Blood Cancer Journal|February 13, 2025
Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation blockJiexian Ma, Shunrong Sun, Yanhui Xie, et al.
Medicine|January 5, 2019
PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancerQi Jiang, Mixue Xie, Mengye He, et al.
Cancer|March 7, 2023
Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemiaMixue Xie, Ting Shi, Qi Jiang, et al.
Cancers|August 7, 2021
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-AnalysisWen Lei, Mixue Xie, Qi Jiang, et al.
Cancer Cell International|July 27, 2021
Significance of initial, interim and end-of-therapy <sup>18</sup>F-FDG PET/CT for predicting transformation risk in follicular lymphomaMixue Xie, Lulu Wang, Qi Jiang, et al.
Frontiers in Immunology|September 15, 2022
Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developmentsQi Jiang, Mixue Xie, Ruyin Chen, et al.
Blood Cancer Journal|November 2, 2025
Glofitamab combined with tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: a single-center pilot trialDe Zhou, Wenjuan Yu, Mixue Xie, et al.
Pageof 4